Unique Wealth Strategies LLC Acquires Shares of 11,610 Sanofi (NASDAQ:SNY)

Unique Wealth Strategies LLC bought a new stake in shares of Sanofi (NASDAQ:SNY) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 11,610 shares of the company’s stock, valued at approximately $577,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Rise Advisors LLC grew its holdings in shares of Sanofi by 98.4% during the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after buying an additional 251 shares in the last quarter. Salem Investment Counselors Inc. acquired a new position in Sanofi in the fourth quarter worth approximately $27,000. Venturi Wealth Management LLC raised its position in Sanofi by 163.5% during the fourth quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock valued at $27,000 after acquiring an additional 332 shares in the last quarter. Farmers & Merchants Trust Co of Chambersburg PA raised its position in Sanofi by 115.6% during the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 746 shares of the company’s stock valued at $37,000 after acquiring an additional 400 shares in the last quarter. Finally, CNB Bank bought a new position in Sanofi during the third quarter valued at approximately $39,000. Institutional investors own 10.04% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. TheStreet lowered shares of Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. Finally, Morgan Stanley initiated coverage on Sanofi in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price target for the company. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $55.00.

Sanofi Trading Down 0.5 %

Shares of SNY traded down $0.23 during mid-day trading on Friday, reaching $49.13. 4,148,180 shares of the company were exchanged, compared to its average volume of 2,214,580. Sanofi has a 52 week low of $42.63 and a 52 week high of $56.26. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. The stock has a market capitalization of $124.28 billion, a PE ratio of 24.69, a PEG ratio of 1.48 and a beta of 0.61. The business has a 50 day simple moving average of $47.71 and a two-hundred day simple moving average of $48.37.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.94 by ($0.05). The business had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $13.02 billion. Sanofi had a net margin of 10.52% and a return on equity of 19.69%. On average, analysts predict that Sanofi will post 4.09 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be paid a $1.478 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a dividend yield of 2.98%. This is a boost from Sanofi’s previous annual dividend of $1.38. Sanofi’s payout ratio is currently 69.35%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.